Format

Send to

Choose Destination
See comment in PubMed Commons below
Neuro Oncol. 2015 Jan;17(1):145-50. doi: 10.1093/neuonc/nou126. Epub 2014 Jul 3.

A prospective open-label study of sirolimus for the treatment of anti-Hu associated paraneoplastic neurological syndromes.

Author information

  • 1Department of Neurology, Erasmus University Medical Center, Rotterdam, Netherlands (A.H.d.J., J.E.B., M.T.d.G., P.A.S.S.); Department of Medical Oncology, Erasmus University Medical Center, Rotterdam, Netherlands (A.H.d.J., J.W.G); Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, Netherlands (T.v.G.); Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, Netherlands (T.v.G.); Department of Immunology, Erasmus University Medical Center, Rotterdam, Netherlands (M.W.S., H.H.).

Abstract

BACKGROUND:

Several lines of evidence suggest a T cell-mediated immune response in paraneoplastic neurological syndromes with anti-Hu antibodies (Hu-PNS). In order to investigate whether suppression of T cell-mediated immune responses in Hu-PNS patients improved their neurological outcome, we performed a prospective open-label, single-arm study on sirolimus.

METHODS:

Seventeen progressive Hu-PNS patients were treated with sirolimus with an intended treatment duration of 8 weeks. Primary outcome measures were (i) functional improvement, defined as a decrease of one or more points on the modified Rankin Scale (mRS), and (ii) improvement of neurological impairment, defined as an increase of one or more points on the Edinburgh Functional Impairment Tests (EFIT).

RESULTS:

One patient showed improvement on both clinical scales (mRS and EFIT). This patient presented with limbic encephalitis and improved dramatically from an mRS score of 3 to mRS 1. Another patient, with subacute sensory neuronopathy, remained stable at mRS 2 and improved one point on the EFIT scale. The other patients showed no improvement on the primary outcome measures. Median survival was 21 months.

CONCLUSION:

We conclude that treatment of Hu-PNS patients with sirolimus may improve or stabilize their functional disabilities and neurological impairments. However, the effects of this T cell-targeted therapy were not better than reported in trials on other immunotherapies for Hu-PNS. Trial Registration https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000793-20/NL.

© The Author(s) 2014. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

KEYWORDS:

paraneoplastic neurological syndromes; sirolimus; treatment

[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk